🦊/Companies

Clearflow

Irvine, US · Founded 2007 · Delaware corporation · 25 employees on LinkedIn · 3 known investors

Find your way into Clearflow

1,052 people in our graph share verified history with the Clearflow team — schools, employers, funds. One of them is your warm intro.

David Phuunlockedknows Hannah Beathard · together at PwC (overlapped)
×8knows the team · via PwC
knows the team · via The University of Chicago Booth School of Business
×2knows the team · via University of Washington

ClearFlow develops PleuraFlow Active Clearance Technology, a device that maintains chest drain patency after cardiac surgery to reduce Retained Blood Syndrome complications, along with products for sternal fixation and reconstruction following sternotomy. The products are used in ICU and surgical settings for post-cardiac-surgery patient care.

Founders & leadership

Clearflow was founded in 2007 by Edward M. Boyle.

EM
Edward M. BoyleinFounderEdward Boyle is a cardiovascular and thoracic surgeon who founded ClearFlow Medical, a venture-backed medical device company focused on cardiac surgery solutions, and previously founded Elixis, a healthcare IT company acquired by General Electric. He completed medical school at the University of Minnesota and cardiothoracic surgery training at the University of Washington.
PMPaul Molloy
Paul MolloyinExecutivePaul Molloy is a CEO and board director with experience across public and private medical device companies, including leadership roles in global operations, R&D, and commercial development. He has led multiple companies through growth phases and exits, including one IPO.
HBHannah Beathard
Hannah BeathardinExecutiveHannah Beathard is Executive Officer at ClearFlow, which develops PleuraFlow Active Clearance Technology, a device designed to maintain chest drain patency after cardiac surgery and reduce complications including Retained Blood Syndrome and postoperative atrial fibrillation.

Board

ASAlexander Suh
Alexander SuhinBoard directorManaging Director at California Technology Ventures
NSNed Scheetz
Ned ScheetzinBoard directorManaging Partner at Aphelion Capital
AD
Andrew D. FirlikBoard director
CM
Christopher MartinBoard director
EM
Edward M. Boyle, Jr.Board director

Investors · 3

Reported raises · per SEC filings

Form D private placements

$49.4M disclosed across 9 rounds · 2011–2025

$2.1MraisedAug 2025 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul MolloyExecutive Officer, Director
  • Alexander SuhDirector
  • Edward M. BoyleDirector
  • Christopher MartinDirector
  • Hannah BeathardExecutive Officer
  • Ned ScheetzDirector
Offering amount
$4M
Amount sold
$2.1M
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$2.3MraisedJun 2024 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Ned ScheetzDirector
  • Hannah BeathardExecutive Officer
  • Paul MolloyExecutive Officer, Director
  • Edward M. BoyleDirector
  • Alexander SuhDirector
  • Christopher MartinDirector
Offering amount
$3M
Amount sold
$2.3M
First sale
Jun 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$7.5MraisedAug 2020 · 5 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher MartinDirector
  • Paul MolloyExecutive Officer, Director
  • Alexander SuhDirector
  • Edward M. BoyleDirector
  • Ned ScheetzDirector
Offering amount
$7.5M
Amount sold
$7.5M
First sale
Aug 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$7.6MraisedMay 2019 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Alexander SuhDirector
  • Paul MolloyExecutive Officer, Director
  • Edward M. BoyleDirector
  • Ned ScheetzDirector
Offering amount
$12M
Amount sold
$7.6M
First sale
May 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$12.5MraisedAug 2018 · 6 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul MolloyExecutive Officer, Director
Offering amount
$12.5M
Amount sold
$12.5M
First sale
Feb 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$5.5MraisedAug 2015 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward M. Boyle, Jr.Director
  • Andrew D. FirlikDirector
  • Ned ScheetzDirector
  • Alexander suhDirector
  • Paul MolloyExecutive Officer, Director
Offering amount
$8.5M
Amount sold
$5.5M
Minimum investment
$2.8M
First sale
Jul 2015
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$2.8MraisedNov 2014 · 3 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Ned ScheetzDirector
  • Andrew D FirlikDirector
  • Edward M Boyle, Jr.Director
  • Paul MolloyExecutive Officer, Director
  • Alexander SuhDirector
Offering amount
$5M
Amount sold
$2.8M
Minimum investment
$240K
First sale
Oct 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$4.2MraisedFeb 2014 · 5 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward M. Boyle, Jr.Director
  • Alexander SuhDirector
  • Ned ScheetzDirector
  • Andrew FirlikDirector
  • Molloy PaulExecutive Officer, Director
Offering amount
$4.2M
Amount sold
$4.2M
Minimum investment
$150K
First sale
Nov 2013
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Clearflow went on to found or lead other companies.

Competitors · 2

by search overlap

Companies competing with Clearflow for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Clearflow do?
ClearFlow develops PleuraFlow Active Clearance Technology, a device that maintains chest drain patency after cardiac surgery to reduce Retained Blood Syndrome complications, along with products for sternal fixation and reconstruction following sternotomy. The products are used in ICU and surgical settings for post-cardiac-surgery patient care.
Who founded Clearflow?
Clearflow was founded by Edward M. Boyle in 2007.
Who are Clearflow's investors?
Clearflow's investors include Aphelion Capital, California Technology Ventures, Oregon Venture Fund.
How much funding has Clearflow raised?
Clearflow has disclosed $49.4M raised across 9 rounds.
Where is Clearflow headquartered?
Clearflow is headquartered in Irvine, US.